Singapore's second commercial biopharmaceutical manufacturing plant will be built by Swiss-based Lonza Group and Singapore's Bio*One Capital. The $350 million large-scale mammalian cell culture plant -- the second in Singapore for commercial biopharmaceuticals manufacturing -- will be completed in 2011.
"The facility will operate with cutting edge technology with a skilled labor force and will be able to manufacture products with a wide array of processes, yields and technologies," said Stefan Borgas, CEO of Lonza.
In February 2006, Lonza and Bio*One entered into an initial joint venture to build Singapore's first commercial-scale biologics manufacturing facility, an 80,000 liter large-scale mammalian biopharmaceutical production facility named Lonza Biologics Singapore Pte Ltd.
The second plant is expected to be constructed over two phases with the Lonza Biologics Tuas shell becoming operational in March 2007 and final build-out completed in 2011. The plant will have a staff of 350.
Singapore's biomedical sciences industry grew 23% in manufacturing output last year.
Interested in information related to this topic? Subscribe to our weekly Value-chain eNewsletter.
